Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days

Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same day Novo's Wegovy HD wins record-fast CNPV approval. Plus Collegium acquires Azstarys for $650M, Pfizer's Talzenna wins in prostatecancer, and Lynavoy gets an early FDA nod.Visit the website at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, retatrutide, Eli Lilly, TRANSCEND-T2D-1, Wegovy HD, Novo Nordisk, semaglutide, CNPV, CollegiumPharmaceutical, Corium, Azstarys, ADHD, Pfizer, Talzenna, talazoparib,TALAPRO-3, prostate cancer, Lynavoy, linerixibat, Alfasigma, GSK, primary biliary cholangitis, CSL, Hemgenix, gene therapy, ACIP, AstraZeneca, Shanghai, obesity, Type 2 diabetes, GLP-1, triple agonist, PARP inhibitor, Lilly, Merck, Sanofi, Moderna